Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-06-06
2006-06-06
Maier, Leigh C. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S646000
Reexamination Certificate
active
07056890
ABSTRACT:
The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss.The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.
REFERENCES:
patent: 4513006 (1985-04-01), Maryanoff et al.
patent: 4792569 (1988-12-01), Maryanoff et al.
patent: 4895845 (1990-01-01), Seed
patent: 5242942 (1993-09-01), Costanzo et al.
patent: 5266591 (1993-11-01), Wierzbicki et al.
patent: 5273993 (1993-12-01), Lo et al.
patent: 5498629 (1996-03-01), Costenzo et al.
patent: 5543405 (1996-08-01), Keown et al.
patent: 5753693 (1998-05-01), Shank
patent: 5753694 (1998-05-01), Shank
patent: 5795895 (1998-08-01), Anchors
patent: 5900418 (1999-05-01), Viner
patent: 6071537 (2000-06-01), Shank
patent: 6201010 (2001-03-01), Cottrell
patent: 6323236 (2001-11-01), McElroy
patent: 6362220 (2002-03-01), Cottrell
patent: WO 00/50020 (2000-08-01), None
patent: WO 00/76493 (2000-12-01), None
Physicians' Desk Reference (1995) entry for “phentermine hydrochloride” pp. 2508-2509.
Carek, P. et al “Current concepts in the pharmacological management of obesity” Drugs (1999) vol 6, pp. 883-904.
Griffen, L. et al “The ‘phen-pro’ diet drug combination . . . ” Arch. Intern. Med. (1998) vol. 158, pp. 1278-1279.
Weintraub, M. et al “A double-blind clinical trial in weight control” Arch. Intern. Med. (1984) vol. 144, pp. 1143-1148.
U.S. Appl. No. 60/139,022, filed Dec. 21, 2000, Najarian.
U.S. Appl. No. 60/178,563, filed Dec. 21, 2000, Najarian.
U.S. Appl. No. 60/181,265, filed Dec. 21, 2000, Najarian.
Physician's Desk Reference, 49thEdition, pp. 2508-2509 (1995).
Bradley et al. (1999), “Bupropion SR with Phentermine for Weight Reduction,”Books of Abstracts, American Psychiactric Association Meeting(distributed to meeting attendees), Washington, D.C. (abstract only).
Bray et al (2002), “Topiramate Produces Dose -Related Weight Loss,”62ndAnnual American Diabetes Association Meeting, San Francisco.
Coyne (1997), letter regarding Ionamin to the U.S. Food and Drug Administration, printed from http://www.fda.gov/medwatch/safety/1997)/ionami2.htm. Sep. 1997.
FDC Reports, Inc. (1999), “Appetite Suppression Drug Excluded by 81% of Employers - PBMI Survey,”The Green Sheet48(19):3.
Gadde et al. (1999), “Bupropion SR in Obesity: A Rendomized Double-Blinded Placebo-Controlled Study,”Obesity Research7(Suppl. 1):51F, Abstract 0136; Annual Meeting of the North American Association for the Study of Obesity, Charlestown, S.C.
Michelucci et al., (1998), “The Preclinical and Therapeutic Activity of the Novel Anticonvulsant Topiramte,”CNS Drug Reviews4(2):165-186.
Penovich et al. (1994), “Weight Loss in Patients Receiving Topiramate for Intractable Epilepsy,”Neurology44(Suppl. 2), Abstract 309P, 46thAnnual Meeting of the American Academy of Neurology, Washington, D.C.
Planet Rx, Inc. (1999), “Drug Therapies”,Fastin, Ionamin (Phentermine), pp. 3-4, printed from http://www.obesity.com.
Potter et al., (1997), “Sustained Weight Loss Associated with 12-Month Topiramate Therapy,”Epilepsia38(Suppl.8):97; Annual Meeting of the American Epilepsy Society, Boston MA.
Raritan (2002), “Clinical Development of Topiramate for Obesity Extended to Simplify Dosing, Improve Tolerability,” Johnson & Johnson Pharmaceutical Research & Development, LLC press release, printed from http://www.jnj.com
ews finance/448.htm. Feb. 2002.
U.S. Food and Drug Administration (1997) “FASTIN (Phentermine HCI) Capsules,”Oct. 1997 Drug Labeling Changes, printed from http://www.fda.gov/medwatch/safety/1997/oct97.htm.
U.S. Food and Drug Administration (1999), “IONAMINE (Phentermine Resin) Capsules,”Feb. 1998 Drug Labeling Changes, printed from http://www.fda.gov/medwatch/safety/1998.feb99.htm.
Zarate (2000), “Antipsychotic Drug Side Effect Issues in Bipolar Manic Patients,”J. Clin. Psychiatry61(Suppl. 8):52-61, Derwent.
Maier Leigh C.
Reed Dianne E.
Reed I. P. Law Group
VIVUS, Inc.
LandOfFree
Combination therapy for effecting weight loss and treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy for effecting weight loss and treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for effecting weight loss and treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3670331